Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance

Accurate identification of breast cancer patients most likely to benefit from adjuvant systemic therapies is crucial. Better understanding of differences between methods can lead to an improved ER, PgR, and HER-2 assessment. The purpose of this preplanned translational research is to investigate the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Viale, Giuseppe, Slaets, Leen, de Snoo, Femke A., Bogaerts, Jan, Russo, Leila, van’t Veer, Laura, Rutgers, Emiel J. T., Piccart-Gebhart, Martine J., Stork-Sloots, Lisette, Dell’Orto, Patrizia, Glas, Annuska M., Cardoso, Fatima
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2016
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4764628/
https://ncbi.nlm.nih.gov/pubmed/26820652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3690-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados